Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Raymond James Financial heads into its October 28 earnings date with a 10% monthly price decline, a flurry of fresh analyst moves, and options positioning that has shifted meaningfully more defensive over recent weeks.
The most telling signal this week is in options. Put/call ratio has climbed to 0.68, well above its 20-day average of 0.55 and running about 1.4 standard deviations above that mean. While far from the 52-week high of 1.63, the direction of travel is clear: since mid-September the ratio has been drifting upward from readings in the low-to-mid 0.40s, suggesting investors have been steadily adding downside protection as the stock slid. The 11% drawdown from the highs has not prompted the usual call-buying bounce, which is worth noting with three weeks to the print.
Short interest tells a far less alarming story. At 3.7% of the free float, borrowing is modest and has actually declined about 7% over the past month, even as the stock sold off. Cost to borrow is minimal at 0.35%, and the lending pool is anything but strained: availability is running above 4,000% of short interest, meaning shares to borrow are vastly more plentiful than demand for them. The ORTEX short score of 42 ranks in the lower third of the universe. None of this points to a short-driven selloff; the pressure has come from elsewhere.
The Street has been busy this week, and the picture is mixed rather than directionally decisive. Barclays raised its target marginally to $197 while holding Overweight, one of the few outright bulls among the recent movers. Bank of America, also on the sidelines with a Neutral, lifted its target to $198. JPMorgan raised to $185, again Neutral. Against those mild lifts, BMO Capital trimmed its target from $175 to $170, keeping Market Perform, and Wells Fargo kicked off coverage at Equal-Weight with a $172 target. The mean target across the analyst base sits at $185.64, implying roughly 16% upside from the current price of $159.43. Yet the clustering of Neutral and Hold ratings tells the real story: the Street broadly sees value here but is not convinced the near-term setup is clean enough to buy aggressively. The bull case centres on the firm's 8,900-plus advisor network managing over $1.7 trillion in client assets, strong free cash flow and around $1.8 billion of excess capital, with agentic AI deployment cited as a longer-term efficiency lever. Bears focus on pressure to net interest income and cash sweep revenues, rising expenses squeezing margins, and the risk that capital markets conditions or rate moves turn less favourable.
Factor scores add texture to the valuation debate. EPS momentum is genuinely exceptional: the 30-day reading ranks in the 98th percentile and the 90-day in the 95th, meaning earnings revisions have been running strongly positive across the analyst community. The analyst recommendation differential also ranks in the 91st percentile, pointing to a consensus that has been improving. That sits awkwardly against a P/E multiple that has compressed about 3 points over the past month to just over 10 times, and a price-to-book ratio that has fallen nearly 0.5 points to 1.98 over the same period. The stock is re-rating cheaper even as estimate momentum remains strong.
On the company's own banking data, Raymond James's insured bank subsidiary has grown net loans and leases for nine consecutive quarters, with the balance reaching $56.2 billion as of the April quarter. Total assets have risen for six straight quarters to $69.9 billion. The FDIC call report dataset is currently untested against the company's reported figures, so no directional read-across to the earnings print is possible. The data does confirm that the bank segment has been expanding consistently, which bears on the bear case argument around loan-to-deposit ratios and balance sheet risk heading into a more uncertain rate environment.
Insider activity in the trailing 90 days tilted toward selling. The Chief Admin Officer sold 7,500 shares in late August for just over $1.3 million. The President of the Private Client Group sold 10,000 shares in late July for approximately $1.76 million. Neither transaction was made under a 10b5-1 plan. Net of all transactions, insiders were net sellers of roughly 23,270 shares worth about $4.1 million over the period. These are not large relative to the float, but the absence of any discretionary open-market buying ahead of what will be a significant quarterly test is a quiet data point.
Among close peers, LPLA gained nearly 8% on the week while SCHW fell 2.3% and AMP was flat. The divergence within the wealth management and brokerage group suggests the selloff in RJF has been more company-specific than a broad sector move, keeping the October 28 earnings report the clearest near-term event to watch.
See the live data behind this article on ORTEX.
Open RJF on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
